Editorial: metabolomic biomarkers for colorectal adenocarcinoma and in the differentiation between irritable bowel syndrome and ulcerative colitis in clinical remission - confounded by the gut microbiome? Authors' reply
Aliment Pharmacol Ther
.
2019 Apr;49(8):1088-1089.
doi: 10.1111/apt.15200.
Authors
Ammar Hassanzadeh Keshteli
1
,
Karen L Madsen
1
,
Rupasri Mandal
2
,
Guy E Boeckxstaens
3
,
Premysl Bercik
4
,
Giada De Palma
4
,
David E Reed
5
,
David Wishart
2
6
,
Stephen Vanner
5
,
Levinus A Dieleman
1
Affiliations
1
Department of Medicine, University of Alberta, Edmonton, AB, Canada.
2
Department of Biological Sciences, University of Alberta, Edmonton, AB, Canada.
3
Department of Gastroenterology, Catholic University of Leuven, Leuven, Belgium.
4
Department of Medicine, Farncombe Family Digestive Research Institute, McMaster University, Hamilton, ON, Canada.
5
Gastrointestinal Diseases Research Unit, Queen's University, Kingston, ON, Canada.
6
Department of Computing Science, University of Alberta, Edmonton, AB, Canada.
PMID:
30920043
DOI:
10.1111/apt.15200
No abstract available
Publication types
Editorial
Comment
MeSH terms
Adenocarcinoma*
Biomarkers
Colitis, Ulcerative*
Colorectal Neoplasms*
Gastrointestinal Microbiome*
Humans
Irritable Bowel Syndrome*
Substances
Biomarkers